Advances of neuroimaging in chemotherapy related cognitive impairment (CRCI) of patients with breast cancer

Effects of D‐CAG chemotherapy regimen on cognitive function in patients with acute myeloid leukaemia: A resting‐state functional magnetic resonance imaging study

“…The development of MRI technology has made it possible to explore the structural and functional abnormalities of brain regions, as well as structural and functional connectivity between different brain regions in cancer patients before and after chemotherapy (Sim o et al, 2013). Previous neuroimaging studies had revealed abnormal brain activities, impaired white matter integrity, and decreased grey matter in cancer patients who underwent chemotherapy, and these abnormalities were related with the degree of cognitive decline of patients (Cheung & Chan, 2013;Sim o et al, 2013;Yao et al, 2023).…”

Cancer related cognitive impairment: a downside of cancer treatment

“…The bulk of our understanding of chemotherapy-associated CRCI stems from studies of cognitive impairment in BC survivors during and after chemotherapy treatment (summarized in Table 1 ) ( 19 , 29 , 64 , 80 – 82 ). BC patients after chemotherapy treatment report deficits in cognitive domains consisting of executive function, working memory, attention, concentration, processing speed, cognitive flexibility, visual and verbal memory ( 83 ).…”

“…Mechanistically, numerous studies have implicated systemic inflammation as a major contributor to chemotherapy-associated CRCI in BC patients. Chemotherapy associated inflammation is a potential significant contributor to CRCI; a thorough review of this subject is beyond the scope of the paper but has been well described in recent years ( 15 , 80 , 81 ). Chemotherapy agents have been reported to elevate multiple pro-inflammatory markers including interlukin-6 (IL-6), IL-1 beta (IL-1β), IL-5, IL-10, reactive oxygen species (ROS), IL-8, interferon gamma (IFN-α), IL-12, IL-17, and tumor necrosis factor alpha (TNF-α) ( 15 , 82 ).…”